Grifols (NASDAQ:GRFS) Shares Gap Down - Time to Sell?

Shares of Grifols, S.A. (NASDAQ:GRFS - Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $8.73, but opened at $8.39. Grifols shares last traded at $8.49, with a volume of 91,998 shares.

Grifols Trading Down 4.5 %

The stock has a fifty day simple moving average of $8.75 and a 200 day simple moving average of $7.74. The company has a current ratio of 1.68, a quick ratio of 0.80 and a debt-to-equity ratio of 1.06.

Grifols (NASDAQ:GRFS - Get Free Report) last posted its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 EPS for the quarter, missing analysts' consensus estimates of $0.23 by ($0.21). The company had revenue of $1.96 billion during the quarter. As a group, analysts predict that Grifols, S.A. will post 0.79 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Grifols

Institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC boosted its holdings in shares of Grifols by 49.4% during the 3rd quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 1,135 shares during the last quarter. Signaturefd LLC boosted its stake in Grifols by 66.2% during the third quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company's stock valued at $48,000 after buying an additional 2,153 shares during the last quarter. Cohen Investment Advisors LLC purchased a new position in Grifols during the 1st quarter valued at approximately $80,000. AQR Capital Management LLC bought a new stake in Grifols in the 2nd quarter worth approximately $89,000. Finally, Cetera Advisors LLC purchased a new stake in shares of Grifols during the 1st quarter worth approximately $147,000.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.